01 — What is it?
Mitochondria-targeted peptide studied in mitochondrial disorders, cardiac and neurologic settings. Clinical development has produced mixed results depending on indication and endpoint.
Database / Research Profiles / SS-31
RESEARCH PROFILE
SS-31
Elamipretide • mitochondria-targeted tetrapeptide
MitochondrialHuman clinical trials; mixed/limited efficacy
EVIDENCE SNAPSHOTHUMAN CLINICAL TRIALS; MIXED/LIMITED EFFICACY
Human clinical trials exist, but efficacy has not been established broadly and regulatory status remains investigational.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Mitochondrial. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED
Human clinical trials exist, but efficacy has not been established broadly and regulatory status remains investigational.
04 — Mechanism / biology
Mitochondria-targeted peptide studied in mitochondrial disorders, cardiac and neurologic settings. Clinical development has produced mixed results depending on indication and endpoint.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.